Method of identifying Anti-siglec antibodies possessing CIS-trans converter properties, Anti-siglec antibodies and use thereof

A method for identifying Siglec-binding molecules with cis-trans converter properties addresses the challenge of ineffective B cell targeting in autoimmune disease treatments, enabling enhanced therapeutic responses through bicistronic gene expression and antibody design.

WO2025190311A1 Publication Date: 2025-09-18SINOMAB BIOSCI
6 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2025/082069
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-03-12
Filing Date
2025-03-12
Publication Date
2025-09-18

AI Technical Summary

Technical Problem

Current treatments for autoimmune diseases, such as rheumatoid arthritis, often fail to effectively target B cells, leading to incomplete responses and potential side effects, while the identification of Siglec-binding molecules with cis-trans converter properties for therapeutic intervention is challenging and laborious.

Method used

A method is developed to identify Siglec-binding molecules, like anti-CD22 antibodies, by co-expressing them with Siglec on a cell surface, incubating with a ligand, and comparing binding amounts to determine cis-trans converter properties, using a specially designed nucleotide cassette for bicistronic gene expression.

Benefits of technology

This approach facilitates the identification of antibodies with enhanced cis-trans converter capabilities, potentially providing more effective immunomodulatory effects and therapeutic outcomes for autoimmune diseases.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

Provided are a method of identifying a sialic acid binding immunoglobulin-type lectin (Siglec) -binding molecule possessing cis-trans converter properties upon binding to the Siglec; a vector comprising a nucleic acid molecule encoding an Siglec-binding molecule and a nucleic acid molecule encoding the Siglec; a host cell comprising the vector; an anti-CD22 antibody; a pharmaceutical composition comprising the anti-CD22 antibody and a pharmaceutically acceptable excipient, diluent or carrier; a method of preventing or treating an autoimmune disease or a neurological disease; and a method of identifying a sialic acid binding immunoglobulin-type lectin (Siglec)-binding molecule lacking cis-trans converter properties upon binding to the Siglec.
Need to check novelty before this filing date? Find Prior Art